SBW Life Science Provides Collateral to Third Parties Worth 7.8 Billion KRW

SBW Life Science announced on the 19th that it has decided to provide collateral worth 7.8 billion KRW to its subsidiary Enrich Holdings. The collateral amount represents 24.14% of its equity capital. The collateralized asset is the first-priority preferential beneficiary right under a real estate trust contract, with the period from November 5, 2022, to November 4, 2023.